Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 26;23(1):903.
doi: 10.1186/s12885-023-11404-1.

Etiological analysis of infection after CRS + HIPEC in patients with PMP

Affiliations

Etiological analysis of infection after CRS + HIPEC in patients with PMP

Rui Yang et al. BMC Cancer. .

Abstract

Background: Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) is the standard treatment for pseudomyxoma peritonei (PMP). It can significantly prolong the survival of patients, but at the same time may increase the risk of postoperative infection.

Method: Patients with PMP who underwent CRS + HIPEC at our center were retrospectively analyzed. According to PMP patients, basic clinical data and relevant information of postoperative infection, we analyzed the common sites of postoperative infection, results of microbial culture and the antibiotics sensitivity. Univariate and multivariate analysis were performed to explore infection-related risk factors.

Result: Among the 482 patients with PMP, 82 (17.0%) patients were infected after CRS + HIPEC. The most common postoperative infection was central venous catheter (CVC) infection (8.1%), followed by abdominal-pelvic infection (5.2%). There were 29 kinds of microbes isolated from the culture (the most common was Staphylococcus epidermidis), including 13 kinds of Gram-positive bacteria, 12 kinds of Gram-negative bacteria, and 4 kinds of funguses. All the antibiotics sensitivity results showed that the most sensitive antibiotics were vancomycin to Gram-positive bacteria (98.4%), levofloxacin to Gram-negative bacteria (68.5%), and fluconazole to fungus (83.3%). Univariate and multivariate analysis revealed the infection independent risk factors as follow: intraoperative blood loss ≥ 350 mL (P = 0.019), ascites volume ≥ 300 mL (P = 0.008).

Conclusion: PMP patients may have increased infection risk after CRS + HIPEC, especially CVC, abdominal-pelvic and pulmonary infections. The microbial spectrum and antibiotics sensitivity results could help clinicians to take prompt prophylactic and therapeutic approaches against postoperative infection for PMP patients.

Keywords: Antibiotic; Bacteria; CRS + HIPEC; PMP; postoperative infection.

PubMed Disclaimer

Conflict of interest statement

The authors report there are no competing interests to declare.

Figures

Fig. 1
Fig. 1
Survival analysis. A Overall survival analysis of all PMP patients; (B) Survival curve analysis of infected group and non-infected group

Similar articles

Cited by

References

    1. Carr NJ, Cecil TD, Mohamed F, et al. A consensus for classification and pathologic reporting of pseudomyxoma peritonei and associated appendiceal neoplasia: the results of the Peritoneal Surface Oncology Group International (PSOGI) modified Delphi process. Am J Surg Pathol. 2016;40(1):14–26. doi: 10.1097/PAS.0000000000000535. - DOI - PubMed
    1. Smeenk RM, Bruin SC, van Velthuysen ML, et al. Pseudomyxoma peritonei. Curr Probl Surg. 2008;45(8):527–575. doi: 10.1067/j.cpsurg.2008.04.003. - DOI - PubMed
    1. Smeenk RM, van Velthuysen ML, Verwaal VJ, et al. Appendiceal neoplasms and pseudomyxoma peritonei: a population based study. Eur J Surg Oncol. 2008;34(2):196–201. doi: 10.1016/j.ejso.2007.04.002. - DOI - PubMed
    1. Mittal R, Chandramohan A, Moran B. Pseudomyxoma peritonei: natural history and treatment. Int J Hyperthermia. 2017;33(5):511–519. doi: 10.1080/02656736.2017.1310938. - DOI - PubMed
    1. Yang R, Su YD, Ma R, et al. Clinical epidemiology of peritoneal metastases in China: The construction of professional peritoneal metastases treatment centers based on the prevalence rate. Eur J Surg Oncol. 2023;49(1):173–178. doi: 10.1016/j.ejso.2022.08.023. - DOI - PubMed

MeSH terms

Substances